Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.

Abstract

Many patients with bone marrow failure syndromes need frequent transfusions of red blood cells, and most of them eventually suffer from organ dysfunction induced by excessively accumulated iron. The only way to treat transfusion-induced iron overload is iron chelating therapy. However, most patients have not been treated effectively because daily/continuous administration of deferoxamine is difficult for outpatients. Recently, a novel oral iron chelator, deferasirox, has been developed, and introduction of the drug may help many patients benefit from iron chelation therapy. In this review, we will discuss the current status of iron overload in transfusion-dependent patients, and the development of Japanese guidelines for the treatment of iron overload in Japan, which were established by the National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan.

• Authors: Takahiro Suzuki, Masao Tomonaga, Yasushi Miyazaki, Shinji Nakao, Kazuma Ohyashiki, Itaru Matsumura, Yutaka Kohgo, Yoshiro Niitsu, Seiji Kojima, Keiya Ozawa
• Journal: International journal of hematology (Int J Hematol) Vol. 88 Issue 1 Pg. 30-35 (Jul 2008) ISSN: 0925-5710 [Print] Japan
• PMID: 18581199 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Benzoates
• Iron Chelating Agents
• Triazoles
• Deferasirox

Topics

• Asian People
• Benzoates (therapeutic use)
• Bone Marrow Diseases (complications, epidemiology, therapy)
• Data Collection
• Deferasirox
• Erythrocyte Transfusion (adverse effects)
• Humans
• Iron Chelating Agents (therapeutic use)
• Iron Overload (drug therapy, epidemiology, etiology)
• Japan
• Practice Guidelines as Topic
• Syndrome
• Triazoles (therapeutic use)